-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Ligand Pharmaceuticals announced that it will spin off OmniAb, the company’s antibody platform business in partnership with Johnson & Johnson, and inject $70 million into the company
.
It is understood that the divestiture is initially scheduled for the first half of this year
.
In fact, the California-based biopharmaceutical company has said it has been considering multiple possibilities for OmniAb's future since last November, including the potential to become an independent public company through an initial public offering
.
The analysis believes that from the perspective of long-term development, the divestment of the business will accelerate the realization of Ligand Pharmaceuticals' strategic layout and enhance the ability of sustainable operation and healthy development
.
It is worth noting that, in addition to foreign companies, since the beginning of this year, with the normalization of centralized drug procurement and the continuous advancement of medical insurance negotiations, many local companies have also chosen to actively focus on their main business and accelerate "slimming" in order to have a better development status.
.
It is reported that since the beginning of the year, a large number of pharmaceutical companies, including Ruikang Pharmaceutical, Yunnan Baiyao, and Xianju Pharmaceutical, have announced that they will divest their assets
.
For example, on January 29, VTR Express disclosed the "Report on the Sale of Major Assets and Related Party Transactions (Draft)", which proposed to sell all the shares of the three target companies held by Xinhexin, Keyixin and Lihua Pharmaceutical in cash
.
According to the data, VTR is mainly engaged in the research and development, production, sales and service of biological enzyme preparations, steroid hormone APIs, functional feed additives and other products, and provides customers with overall biotechnology solutions
.
On January 19, Ruikang Pharmaceutical announced that the company planned to transfer 51% of Honglin Pharmaceuticals shares, and Wang Hongliang took over
.
According to the announcement, the legal representative of Honglin Pharmaceutical is Wang Hongliang, and the company's business scope includes Chinese patent medicine, Chinese herbal decoction pieces, and chemical pharmaceutical preparations
.
The company was previously held 51% by Ruikang Pharmaceuticals and 49% by Wang Hongliang, and is currently wholly-owned by Wang Hongliang
.
On January 18, Xianju Pharmaceutical announced that it plans to transfer 61.
2% of the equity of its holding subsidiary Haisheng Pharmaceutical, and will no longer hold the company's equity after the transfer is completed..
It is reported that the main business of its subsidiary Haisheng Pharmaceutical is the manufacture of vitamin D3 APIs.
Due to the continuous investment in subsequent production transformation and new product expansion, it is uncertain.
Xianju Pharmaceutical will focus on steroid hormones according to its development plan.
Therefore, the company chose to list and transfer the equity
.
Prior to this, Xianju Pharmaceutical also transferred part of the waste machinery and equipment assets in the Chengnan plant at a transaction price of 20.
3316 million yuan
.
On January 12, Asia Pacific Pharmaceuticals announced that the shareholder Bank of Ningbo plans to transfer the 39 million shares it holds to Fubon Group through a transfer agreement, with a total transfer price of RMB 203.
19 million
.
After the completion of the share transfer, Fubon Group's shareholding ratio will increase to 14.
38%
.
.
.
.
The industry believes that behind these actions, there is a turbulent pharmaceutical market; at the same time, it also indicates that the market competition among pharmaceutical companies is becoming more intense, and the industry reshuffle is also accelerating
.
In the future, under the background of the accelerated development of the pharmaceutical industry, the industry expects that activities such as asset divestitures, cooperation and exchanges of pharmaceutical companies will become more frequent and normalized
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
It is understood that the divestiture is initially scheduled for the first half of this year
.
In fact, the California-based biopharmaceutical company has said it has been considering multiple possibilities for OmniAb's future since last November, including the potential to become an independent public company through an initial public offering
.
The analysis believes that from the perspective of long-term development, the divestment of the business will accelerate the realization of Ligand Pharmaceuticals' strategic layout and enhance the ability of sustainable operation and healthy development
.
It is worth noting that, in addition to foreign companies, since the beginning of this year, with the normalization of centralized drug procurement and the continuous advancement of medical insurance negotiations, many local companies have also chosen to actively focus on their main business and accelerate "slimming" in order to have a better development status.
.
It is reported that since the beginning of the year, a large number of pharmaceutical companies, including Ruikang Pharmaceutical, Yunnan Baiyao, and Xianju Pharmaceutical, have announced that they will divest their assets
.
For example, on January 29, VTR Express disclosed the "Report on the Sale of Major Assets and Related Party Transactions (Draft)", which proposed to sell all the shares of the three target companies held by Xinhexin, Keyixin and Lihua Pharmaceutical in cash
.
According to the data, VTR is mainly engaged in the research and development, production, sales and service of biological enzyme preparations, steroid hormone APIs, functional feed additives and other products, and provides customers with overall biotechnology solutions
.
On January 19, Ruikang Pharmaceutical announced that the company planned to transfer 51% of Honglin Pharmaceuticals shares, and Wang Hongliang took over
.
According to the announcement, the legal representative of Honglin Pharmaceutical is Wang Hongliang, and the company's business scope includes Chinese patent medicine, Chinese herbal decoction pieces, and chemical pharmaceutical preparations
.
The company was previously held 51% by Ruikang Pharmaceuticals and 49% by Wang Hongliang, and is currently wholly-owned by Wang Hongliang
.
On January 18, Xianju Pharmaceutical announced that it plans to transfer 61.
2% of the equity of its holding subsidiary Haisheng Pharmaceutical, and will no longer hold the company's equity after the transfer is completed..
It is reported that the main business of its subsidiary Haisheng Pharmaceutical is the manufacture of vitamin D3 APIs.
Due to the continuous investment in subsequent production transformation and new product expansion, it is uncertain.
Xianju Pharmaceutical will focus on steroid hormones according to its development plan.
Therefore, the company chose to list and transfer the equity
.
Prior to this, Xianju Pharmaceutical also transferred part of the waste machinery and equipment assets in the Chengnan plant at a transaction price of 20.
3316 million yuan
.
On January 12, Asia Pacific Pharmaceuticals announced that the shareholder Bank of Ningbo plans to transfer the 39 million shares it holds to Fubon Group through a transfer agreement, with a total transfer price of RMB 203.
19 million
.
After the completion of the share transfer, Fubon Group's shareholding ratio will increase to 14.
38%
.
.
.
.
The industry believes that behind these actions, there is a turbulent pharmaceutical market; at the same time, it also indicates that the market competition among pharmaceutical companies is becoming more intense, and the industry reshuffle is also accelerating
.
In the future, under the background of the accelerated development of the pharmaceutical industry, the industry expects that activities such as asset divestitures, cooperation and exchanges of pharmaceutical companies will become more frequent and normalized
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
